View in EDS

Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.

Saved in:
Bibliographic Details
Title: Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.
Authors: Horn, L.1, Gettinger, S.2, Camidge, R.3, Smit, E.4, Janjigian, Y.5, Pao, W.1, Schnell, D.6, Wang, B.7, Chand, V.7, Groen, H.8
Source: International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS39-S40. 1p.
Subjects: Cetuximab, Gefitinib, Lung cancer treatment, Metastasis, Skin inflammation, Medical statistics
Database: Engineering Source
FullText Text:
  Availability: 0
Header DbId: egs
DbLabel: Engineering Source
An: 98846273
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Horn%2C+L%2E%22">Horn, L.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Gettinger%2C+S%2E%22">Gettinger, S.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Camidge%2C+R%2E%22">Camidge, R.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Smit%2C+E%2E%22">Smit, E.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Janjigian%2C+Y%2E%22">Janjigian, Y.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Pao%2C+W%2E%22">Pao, W.</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Schnell%2C+D%2E%22">Schnell, D.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Wang%2C+B%2E%22">Wang, B.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Chand%2C+V%2E%22">Chand, V.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Groen%2C+H%2E%22">Groen, H.</searchLink><relatesTo>8</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22International+Journal+of+Radiation+Oncology%2C+Biology%2C+Physics%22">International Journal of Radiation Oncology, Biology, Physics</searchLink>. Nov2014 Supplement, Vol. 90 Issue 5, pS39-S40. 1p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Cetuximab%22">Cetuximab</searchLink><br /><searchLink fieldCode="DE" term="%22Gefitinib%22">Gefitinib</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+cancer+treatment%22">Lung cancer treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Metastasis%22">Metastasis</searchLink><br /><searchLink fieldCode="DE" term="%22Skin+inflammation%22">Skin inflammation</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+statistics%22">Medical statistics</searchLink>
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=egs&AN=98846273
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ijrobp.2014.08.220
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S39
    Subjects:
      – SubjectFull: Cetuximab
        Type: general
      – SubjectFull: Gefitinib
        Type: general
      – SubjectFull: Lung cancer treatment
        Type: general
      – SubjectFull: Metastasis
        Type: general
      – SubjectFull: Skin inflammation
        Type: general
      – SubjectFull: Medical statistics
        Type: general
    Titles:
      – TitleFull: Continued Afatinib (A) With the Addition of Cetuximab (C) After Progression on Afatinib in Patients With Acquired Resistance (AR) to Gefitinib (G) or Erlotinib (E): Metastatic Non-Small Cell Lung Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Horn, L.
      – PersonEntity:
          Name:
            NameFull: Gettinger, S.
      – PersonEntity:
          Name:
            NameFull: Camidge, R.
      – PersonEntity:
          Name:
            NameFull: Smit, E.
      – PersonEntity:
          Name:
            NameFull: Janjigian, Y.
      – PersonEntity:
          Name:
            NameFull: Pao, W.
      – PersonEntity:
          Name:
            NameFull: Schnell, D.
      – PersonEntity:
          Name:
            NameFull: Wang, B.
      – PersonEntity:
          Name:
            NameFull: Chand, V.
      – PersonEntity:
          Name:
            NameFull: Groen, H.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 11
              Text: Nov2014 Supplement
              Type: published
              Y: 2014
          Identifiers:
            – Type: issn-print
              Value: 03603016
          Numbering:
            – Type: volume
              Value: 90
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: International Journal of Radiation Oncology, Biology, Physics
              Type: main
ResultId 1